Drug Trial Radar · NCT04829318
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Apr 26, 2021
Primary completion
Jul 22, 2024
Study completion Jul 22, 2024
Sponsor
- Lead sponsor
- Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).
Conditions
- Depressive Disorder, Major
Interventions
EsketamineDrug
Esketamine will be self-administered as nasal spray.
SSRI/SNRIDrug
Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Incidence Rate of Treatment-emergent Adverse Events (TEAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Percentage of of Participants With TEAEs Leading to DeathTime frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Incidence Rate of TEAEs Leading to DeathTime frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Percentage of Participants With Treatment-emergent AEs of Special Interest (AESIs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Incidence Rate of Treatment-emergent AEs of Special Interest (AESIs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
- Number of Participants With Suicidal Ideation and Behavior in Study 54135419TRD4010 as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) ScoreTime frame: Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)
Locations
59 sites in 14 countries. Site status is shown where the registry gives one.
FunDaMos
Buenos Aires, Argentina
CEN Consultorios Especializados en Neurociencias
Córdoba, Argentina
Fundacion Lennox
Córdoba, Argentina
Instituto Medico DAMIC
Córdoba, Argentina
Sanatorio Prof Leon S Morra S A
Córdoba, Argentina
Instituto de Neurociencias San Agustin
La Plata, Argentina
C I A P Centro de investigacion y Asistencia en Psiquiatria
Rosario, Argentina
Anima
Alken, Belgium
Mental Health Center - Rousse
Rousse, Bulgaria
Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
Sofia, Bulgaria
Centre for Mental Health Prof.N.Shipkovenski EOOD
Sofia, Bulgaria
Psychiatricka ambulance Saint Anne s.r.o.
Brno, Czechia
Psychiatricka ambulance, MUDr. Marta Holanova
Brno, Czechia
NeuropsychiatrieHK, s.r.o.
Hradec Králové, Czechia
A Shine S R O
Pilsen, Czechia
AD71 s.r.o.
Prague, Czechia
Medical Services Prague S R O
Prague, Czechia
Institut Neuropsychiatricke pece
Prague, Czechia
Mederon LTD at ARTES
Helsinki, Finland
Medizinisches Versorgungszentrum LiO GmbH
Berlin, Germany
Praxis Dr. med. Kirsten Hahn
Berlin, Germany
Klinikum Dortmund gGmbH
Dortmund, Germany
Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik
Freiburg im Breisgau, Germany
Klinische Forschung Hamburg
Hamburg, Germany
Oberhavel Kliniken GmbH
Hennigsdorf, Germany
Pharmakologisches Studienzentrum Chemnitz GmbH
Mittweida, Germany
Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik
Pfaffenhofen, Germany
Somni Bene GmbH
Schwerin, Germany
Klinische Forschung Schwerin GmbH
Schwerin, Germany
Psychiatric Clinic 'Agios Charalampos'
Heraklion, Greece
University General Hospital of Rio Patras
Pátrai, Greece
G Papanikolaou Hospital of Thessaloniki
Thessaloniki, Greece
Processus Kft
Budapest, Hungary
Bugat Pal Korhaz
Gyöngyös, Hungary
Petz Aladar Megyei Oktato Korhaz
Győr, Hungary
Hospital Raja Permaisuri Bainun
Ipoh, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Hospital Pengajar Universiti Putra Malaysia
Serdang, Malaysia
Hospital Tuanku Jaafar
Seremban, Malaysia
Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
Bialystok, Poland
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.